For evaluation of the risk borne by hospital pharmacy personnel exposed to antineoplastic agents, the incorporation of cyclophosphamide, ifosfamide, and platinum-containing drugs was quantified by the determination of urinary concentrations.
In addition, the induction of micronuclei (MN) and sister-chromatid-exchange (SCE) rates in peripheral blood lymphocytes were studied for correlation with the urinary excretion of cytostatic drugs.
Cyclophosphamide and ifosfamide were determined in 24-h urine samples using gas chromatography with electron capture (detection limit 2.5 mug/l).
Voltammetric analysis enabled the determination of platinum concentrations of 4 ng/l. Heparinized blood (20 ml) was drawn and lymphocytes were cultured for MN and SCE studies.
In all, 13 hospital pharmacists and pharmacy technicians regularly involved in the preparation of cytostatic drugs participated in this investigation (7 persons represent a follow-up group).
All subjects applied standard safety precautions, including the use of a vertical laminar airflow hood, protective gowns, and latex gloves.
On the day of urine sampling an average of 4,870 mg cyclophosphamide, 5,580 mg ifosfamide, and 504 mg platinum-containing drugs were handled.
The excretion of 5 and 9 mug cyclophosphamide/l urine was measured in two samples, respectively.
An elevated level of urinary platinum was found in one pharmacist (22.3 ng/g creatinine) in comparison with a nonexposed control group. (...)
Mots-clés Pascal : Personnel sanitaire, Hôpital, Exposition professionnelle, Médecine travail, Médicament, Anticancéreux, Cyclophosphamide, Ifosfamide, Platine II Complexe, Surveillance biologique, Urine, Liquide biologique, Homme, Test mutagénicité, Cytogénétique, Toxicité, Echange chromatide soeur, Cytostatique, Pharmacie hospitalière
Mots-clés Pascal anglais : Health staff, Hospital, Occupational exposure, Occupational medicine, Drug, Antineoplastic agent, Cyclophosphamide, Ifosfamide, Platinum II Complexes, Biological monitoring, Urine, Biological fluid, Human, Mutagenicity testing, Cytogenetics, Toxicity, Sister chromatid exchange, Cytostatic, Hospital pharmacy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0476978
Code Inist : 002B02U10. Création : 03/02/1998.